Oncological Surgery Unit, Veneto Institute of Oncology (IOV-IRCCS), Padova, Italy.
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.
Neoadjuvant chemoradiotherapy (CT-RT) before esophagectomy seems to affect the number of nodal metastasis and to alter the distribution of those that remain. The aim of this study was to define how neoadjuvant chemoradiotherapy changes nodal metastasis patterns in locally advanced esophageal cancer.
A total of 402 consecutive patients with cancer of the esophagus or esophagogastric junction (181 adenocarcinoma [AC] and 221 squamous cell carcinoma [SCC]) (evaluated at clinical stage T1N1, T2N1, T3N0, or T3N1 and pathological stage M0) presenting in our Department between 1992 and 2007 and who underwent complete resection (R0) were included in this retrospective study on a prospectively collected database. All dissected lymph nodes were retrieved and microscopically analyzed. Nodal metastasis patterns in patients who underwent chemotherapy (CT) or chemoradiotherapy (CT-RT) neoadjuvant therapy were compared with those in patients who underwent surgery alone.
Almost 30% of the adenocarcinoma patients and approximately 40% of the SCC patients showed effective tumor downstaging after neoadjuvant therapy. There were fewer paracardial node metastases (P = .002) in the AC patients who underwent CT-RT neoadjuvant therapy. There were, likewise, significantly fewer paraesophageal, paracardial, and subcarinal node metastases in the SCC patients in whom the perigastric nodes became the second-most frequent site of metastasis.
Not only was frequency of lymph node metastases decreased after neoadjuvant therapy, but nodal localization and pattern were also significantly modified.
术前新辅助放化疗(CT-RT)似乎会影响淋巴结转移的数量,并改变其分布。本研究旨在明确新辅助放化疗如何改变局部晚期食管癌的淋巴结转移模式。
本回顾性研究纳入了 1992 年至 2007 年间在我科就诊的 402 例连续食管癌或食管胃交界部癌患者(181 例腺癌[AC]和 221 例鳞癌[SCC])(临床分期 T1N1、T2N1、T3N0 或 T3N1,病理分期 M0),均行完全切除术(R0),并基于前瞻性收集的数据库进行分析。所有切除的淋巴结均进行了检索和显微镜分析。比较了接受化疗(CT)或放化疗(CT-RT)新辅助治疗的患者与仅接受手术的患者的淋巴结转移模式。
约 30%的腺癌患者和近 40%的鳞癌患者在新辅助治疗后出现肿瘤降期。接受 CT-RT 新辅助治疗的 AC 患者的贲门旁淋巴结转移(P =.002)明显减少。同样,接受新辅助治疗的 SCC 患者中,胃周淋巴结成为第二常见转移部位,食管旁、贲门旁和隆突下淋巴结转移明显减少。
新辅助治疗后淋巴结转移的频率不仅降低,而且淋巴结的定位和分布也发生了显著改变。